Read Mosby's 2014 Nursing Drug Reference Online
Authors: Linda Skidmore-Roth
Canada only Side effects:
italics
= common;
bold
= life-threatening
Nurse Alert
(ox-ay′ze-pam)
Func. class.:
Sedative/hypnotic; antianxiety
Chem. class.:
Benzodiazepine, short acting
Potentiates the actions of GABA, especially in the limbic system and the reticular formation
Anxiety, alcohol withdrawal, insomnia
Pregnancy (D), breastfeeding, children <6 yr, hypersensitivity to benzodiazepines, closed-angle glaucoma, psychosis
Precautions:
Geriatric patients, debilitated, renal/hepatic disease, depression, suicidal ideation, dementia, sleep apnea, seizure disorder
• Adult:
PO
10-30 mg tid-qid, max 120 mg/day
• Geriatric:
PO
5 mg daily-bid initially, may increase, max 15 mg qid
• Adult:
PO
15-30 mg tid-qid
Available forms:
Caps 10, 15, 30 mg
•
Without regard to food
CNS:
Dizziness, drowsiness
, confusion, headache, anxiety, tremors, fatigue, depression, insomnia, hallucinations, paradoxical excitement, transient amnesia
CV:
Orthostatic hypotension
,
ECG changes, tachycardia,
hypotension
EENT:
Blurred vision
, tinnitus, mydriasis
GI:
Nausea, vomiting, anorexia
HEMA:
Leukopenia
INTEG:
Rash, dermatitis, itching
SYST:
Dependence
Peak 2-4 hr; metabolized by liver; excreted by kidneys; half-life 5-15 hr; crosses placenta, breast milk; protein binding 97%
Increase:
oxazepam effects—CNS depressants, alcohol, disulfiram, oral contraceptives
Decrease:
oxazepam effects—oral contraceptives, phenytoin, theophylline, valproic acid
Decrease:
effects of levodopa
Increase:
CNS depression—kava, melatonin, valerian
Increase:
AST, ALT, serum bilirubin
Decrease:
WBC
•
B/P (lying, standing), pulse; if systolic B/P drops 20 mm Hg, hold product, notify prescriber
Mental status: mood, sensorium, affect, sleeping pattern, drowsiness, dizziness,
suicidal thoughts/behaviors
Physical dependency, withdrawal symptoms:
headache, nausea, vomiting, muscle pain, weakness, tremors, seizures (long-term use)
•
Assistance with ambulation during beginning therapy because drowsiness, dizziness occurs
•
Safety measures, including side rails
•
Therapeutic response: decreased anxiety, restlessness, insomnia
•
That product may be taken without regard to food
•
That medication not to be used for everyday stress or used >4 mo unless di
rected by prescriber; not to take more than prescribed dose because product may be habit forming
•
To avoid OTC preparations (cough, cold, hay fever) unless approved by prescriber
•
To avoid driving, activities that require alertness because drowsiness may occur
•
To avoid alcohol, other psychotropic products unless directed by prescriber
•
Not to discontinue product abruptly after long-term use
•
To rise slowly because fainting may occur, especially among geriatric patients
•
That drowsiness may worsen at beginning of treatment
•
To notify prescriber if pregnancy is planned or suspected pregnancy (D)
Canada only Side effects:
italics
= common;
bold
= life-threatening
Nurse Alert
(ox′kar-baz′uh-peen)
Trileptal
Func. class.:
Anticonvulsant
Chem. class.:
CarBAMazepine analog
May inhibit nerve impulses by limiting influx of sodium ions across cell membrane in motor cortex
Partial seizures
Unlabeled uses:
Trigeminal neuralgia, atypical panic disorder, bipolar disorder
Hypersensitivity
Precautions:
Pregnancy (C), breastfeeding, children <4 yr, hypersensitivity to carBAMazepine, renal disease, fluid restriction, hyponatremia, abrupt discontinuation, suicidal ideation
• Adult:
PO
300 mg bid, may be increased by 600 mg/day in divided doses bid at weekly intervals; maintenance 1200 mg/day
• Child 4-16 yr:
PO
8-10 mg/kg/day divided bid; dose determined by weight, increase by 5 mg/kg/day q3days, max doses weight dependent
• Adult:
PO
300 mg bid with reduction in other anticonvulsants; increase OXcarbazepine by 600 mg/day each week over 2-4 wk; withdraw other anticonvulsants over 3-6 wk; max 2400 mg/day
• Adult:
PO
300 mg bid, increase by 300 mg/day q3days to 1200 mg in divided doses bid
• Adult:
PO
CCr <30 ml/min, 150 mg bid, increase slowly
• Adult:
PO
300 mg bid, may increase by ≤600 mg/day
Available forms:
Film-coated tabs 150, 300, 600 mg; oral susp 300 mg/5 ml
•
Without regard to meals
•
Oral susp:
shake well, use calibrated oral syringe provided, use or discard within 7 days of opening
CNS:
Headache, dizziness, confusion, fatigue
, feeling abnormal, ataxia, abnormal gait, tremors, anxiety, agitation,
worsening of seizures, suicidal thoughts/behaviors
CV:
Hypotension
, chest pain, edema
EENT:
Blurred vision, diplopia, nystagmus
, rhinitis, sinusitis
GI:
Nausea, constipation, diarrhea
, anorexia, vomiting, abdominal pain, gastritis
INTEG:
Purpura, rash, acne
SYST:
Angioedema, anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS)
PO:
Onset unknown; peak 4-6 hr; metabolized by liver to active metabolite; terminal half-life 7-9 hr metabolite; inhibits P450 CYP2C19, induces CYP3A4/5
Contraindicated: MAOIs, ranolazine, nisoldipine
Increase:
CNS depression—alcohol
Decrease:
effects—felodipine, oral contraceptive, carBAMazepine
Decrease:
OXcarbazepine levels—carBAMazepine, PHENobarbital, phenytoin, valproic acid, verapamil
Increase:
anticonvulsant effect—ginkgo
Decrease:
anticonvulsant effect—ginseng, santonica
Decrease:
sodium
•
Description of seizures: frequency, duration, aura
•
Hyponatremia: headache, nausea, confusion, usually within the first 3 mo of treatment, but may occur ≤1 yr, if this product is being used with other products that decrease sodium, monitor sodium levels
•
Electrolyte: sodium; T
4
; phenytoin (when given together)
Serious reactions:
angioedema, anaphylaxis, Stevens-Johnson syndrome
•
CNS/mental status: mood, sensorium, affect, behavioral changes, confusion,
suicidal thoughts/behaviors;
if mental status changes, notify prescriber
•
Eye problems: need for ophthalmic exams before, during, after treatment (slit lamp, funduscopy, tonometry)
•
Pregnancy:
lack of seizure control due to MHD, a metabolite of OXcarbazepine, monitor seizure control
•
Storage at room temp
•
Therapeutic response: decreased seizure activity
•
To avoid driving, other activities that require alertness
•
To take twice a day at same intervals
•
Not to discontinue medication quickly after long-term use, seizures may increase
•
To inform prescriber if hypersensitive to carBAMazepine; multisystem hypersensitivity may occur, to report fever, other allergic symptoms
•
To avoid use of alcohol while taking product
•
To use alternative contraception if using hormonal method, to report if pregnancy is planned or suspected pregnancy (C)
•
To report skin rashes immediately, serious skin reactions can occur
Activated charcoal; give 0.9% NaCl (hypotensive state), atropine (bradycardia); use benzodiazepines, barbiturates for seizures